Literature DB >> 32355354

A field comparison of heterologous and homologous routes of administration of modified live vaccines for the control of bovine respiratory disease in recently weaned beef calves.

Nathan Erickson1, John Ellis1, Cheryl Waldner1, Herbert Lardner1, Sheryl Gow1, John Campbell1, Adam Berenik1.   

Abstract

The use of metaphylactic antimicrobials to control bovine respiratory disease (BRD) is under increased scrutiny; therefore, effective immunization is becoming a priority. Stimulation of an effective immune response is challenging because calves are often primed with injectable (IJ) vaccines, in the face of maternal antibodies which can interfere with the immune response. Maternal antibody interference may be bypassed with use of intranasal (IN) vaccines. This study represents one of few independent vaccine field trials and it demonstrated no significant differences in post-weaning BRD morbidity/mortality or average daily gain in beef calves primed with either an IN or IJ vaccine. Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32355354      PMCID: PMC7155885     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  13 in total

1.  Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus following neonatal mucosal priming of beef calves.

Authors:  John Ellis; Sheryl Gow; Adam Berenik; Stacey Lacoste; Nathan Erickson
Journal:  Can Vet J       Date:  2018-12       Impact factor: 1.008

Review 2.  Vaccination of calves against common respiratory viruses in the face of maternally derived antibodies(IFOMA).

Authors:  Manuel F Chamorro; Amelia Woolums; Paul H Walz
Journal:  Anim Health Res Rev       Date:  2016-04-04       Impact factor: 2.615

3.  Efficacy of intranasal vaccination with a multivalent vaccine containing temperature-sensitive modified-live bovine herpesvirus type 1 for protection of seronegative and seropositive calves against respiratory disease.

Authors:  Suman M Mahan; Brian Sobecki; John Johnson; Nancee L Oien; Todd R Meinert; Sarah Verhelle; Sally J Mattern; Terry L Bowersock; Randy D Leyh
Journal:  J Am Vet Med Assoc       Date:  2016-06-01       Impact factor: 1.936

4.  Effect of maternal antibodies on induction and persistence of vaccine-induced immune responses against bovine viral diarrhea virus type II in young calves.

Authors:  J Ellis; K West; V Cortese; C Konoby; D Weigel
Journal:  J Am Vet Med Assoc       Date:  2001-08-01       Impact factor: 1.936

5.  Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV.

Authors:  Ilse Vangeel; Adriaan F G Antonis; Manuela Fluess; Lutz Riegler; Andy R Peters; Silke S Harmeyer
Journal:  Vet J       Date:  2006-12-13       Impact factor: 2.688

Review 6.  Best management practices for newly weaned calves for improved health and well-being.

Authors:  B K Wilson; C J Richards; D L Step; C R Krehbiel
Journal:  J Anim Sci       Date:  2017-05       Impact factor: 3.159

Review 7.  Overview of the North American beef cattle industry and the incidence of bovine respiratory disease (BRD).

Authors:  Delbert G Miles
Journal:  Anim Health Res Rev       Date:  2009-12       Impact factor: 2.615

Review 8.  Heterologous prime-boost vaccination.

Authors:  Shan Lu
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

9.  Evaluation of economic and performance outcomes associated with the number of treatments after an initial diagnosis of bovine respiratory disease in commercial feeder cattle.

Authors:  Natalia Cernicchiaro; Brad J White; David G Renter; Abram H Babcock
Journal:  Am J Vet Res       Date:  2013-02       Impact factor: 1.156

Review 10.  Pathogenesis and pathology of bovine pneumonia.

Authors:  Roger J Panciera; Anthony W Confer
Journal:  Vet Clin North Am Food Anim Pract       Date:  2010-07       Impact factor: 3.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.